Biophar follows strict cold-chain handling protocols, preserving product integrity from manufacturing to end-user delivery
D., Koch, H
More often than not, these free radicals build up in the mitochondria
Journal of nutrition and metabolism, 2015, 760689
2456-C INHIBITION OF THE LYSOPHOSPHATIDIC ACID PATHWAY IMPROVES HEPATIC FIBROSIS AND PORTAL HYPERTENSION IN EXPERIMENTAL ADVANCED CHRONIC LIVER DISEASE Peio Aristu 1 , Zoe Boyer-Diaz 1 , Anna Zagorska 2 , Monika Sharma 2 , Mara Andrs-Rozas 1 , Grant Budas 2 , Jaime Bosch 3 and Jordi Gracia-Sancho 1,3 , (1)Barcelona Liver Bioservices (BLB), (2)Gilead Sciences, Inc., (3)Idibaps - Hospital Clnic Barcelona - Ciberehd, Barcelona, Spain Background: Hepatic necroinflammatory processes are significant contributors to the progression of advanced chronic liver disease (ACLD), characterized by hepatic microvascular dysfunction, fibrosis, and portal hypertension
Clin Trans Sci (2021) 14(4):1390402